Rochester’s Taubman Named Editor of American Heart Association Journal
Thursday, December 21, 2006
Mark Taubman M.D., chief of the Cardiology Division and director of the Cardiovascular Research Institute at the University of Rochester Medical Center, has been named editor-in-chief of the journal Arteriosclerosis, Thrombosis and Vascular Biology(ATVB), one of five medical journals produced by the American Heart Association (AHA). In conjunction with the appointment, the journal offices will move to the University of Rochester and will help focus national and international attention on the University and the region as a major center for the study of Cardiovascular Diseases.
The AHA journals provide up-to-date information on the research, diagnosis and treatment of cardiovascular disease. The five journals, which include Circulation Research, Stroke, Hypertension and Circulation, are peer-reviewed by leading physicians and cardiovascular scientists. ATVB is considered the leading journal in the fields of vascular biology and atherosclerosis and ranks competitively in terms of its measured impact with other major scientific journals. It has offices in Europe and Asia, as well as in the United States, and is read by leading physicians and scientists throughout the world. As editor-in-chief, Dr. Taubman will be responsible for overseeing the activities of all three offices.
ATVB is published monthly under the auspices of The Council on Arteriosclerosis, Thrombosis and Vascular Biology. This AHA body seeks to advance prevention of and treatment for vascular and thrombotic diseases, which involve damage to blood vessels, the formation of blood clots, and that often lead to heart attack and stroke.
“I am greatly honored to be chosen as editor for such an important publication,” said Taubman, also Paul N. Yu Professor of Medicine at the Medical Center. “I look forward to working with the cardiovascular disease community to provide an ideal forum in which to share new ideas and discoveries that advance the treatment and understanding of cardiovascular disease and improve patients' lives.”
As a research leader, Taubman has worked for years to determine why inflammation occurs in blood vessels of patients with atherosclerosis and how this leads to the formation of blood clots. These clots are responsible for unstable coronary syndromes, including angina, heart attacks and sudden death. By understanding the factors that cause clots to form in diseased arteries, new approaches can be developed to prevent heart attacks and stroke.
A search committee composed of scientists and senior AHA leaders considered a list of candidates, each of which wrote statements on their vision for the journal’s future. In his vision statement, Taubman expressed interest in better using the journal as a teaching tool and as a forum for the establishment of treatment guidelines in new areas of the covered fields. Along with his vision, broad expertise in each of the areas covered by the journal, and the fact that he has held several posts with AHA over the years had much to do with his being chosen, Taubman said.
As editor, Taubman will for the next four years oversee an international team of editors and reviewers that will chose for publication 500 scientific papers per year from approximately 2,500 submissions. Each paper signifies a write-up on either a basic or clinical science study, any one of which could signify an important advance in any of the fields covered by the journal. Beyond summarizing data, the journal also publishes review papers that capture the status quo and state of the art on key medical issues or questions, and editorials that describe an expert’s opinion on a debated topic.
The editor-in-chief chooses the associate editors, building the team of professionals that will oversee the review of all the submitted manuscripts in the United States, and also through journal offices in Europe and Asia. Each paper is rated on the quality of the science, on the innovation involved, based on the opinions of expert reviewers. Final content decisions rest with the editor-in-chief and his associate editors.
Dr. Taubman is particularly introduced in presenting research involving new technologies.
”One of the dangers for a journal is that it can settle into a niche in which it is a leader, and not move with important changes in science,” Taubman said. “With that in mind, one of my priorities as editor will be to include studies, reviews and editorials that explore how new technologies are changing the field of vascular biology. How are proteomics and nanotechnology changing vascular medicine, for example? ATVB is a journal that is markedly increasing in international prominence, and my overall goal is to maintain that momentum by pursuing the inclusion of articles that will keep it at the cutting edge.”
# # #